[177Lu‐DOTA0,Tyr3]octreotate for somatostatin receptor‐targeted radionuclide therapy
نویسندگان
چکیده
منابع مشابه
Somatostatin Receptor Based Imaging and Radionuclide Therapy
Somatostatin (SST) receptors (SSTRs) belong to the typical 7-transmembrane domain family of G-protein-coupled receptors. Five distinct subtypes (termed SSTR1-5) have been identified, with SSTR2 showing the highest affinity for natural SST and synthetic SST analogs. Most neuroendocrine tumors (NETs) have high expression levels of SSTRs, which opens the possibility for tumor imaging and therapy w...
متن کاملRadiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.
BACKGROUND Peptide receptor scintigraphy with the radioactive somatostatin analogue, [111In-DTPA0]octreotide, is a sensitive and specific technique to show in vivo the presence and abundance of somatostatin receptors on various tumours. AIM With this technique primary tumours and metastases of neuroendocrine cancers as well as of many other cancer-types can be localised. This technique is cur...
متن کاملPeptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
BACKGROUND Clinical experience with the radiolabeled somatostatin analogues 90Y-DOTATOC and, more recently, 177Lu-DOTATATE, is ongoing since more than a decade in few centers. Dosimetric studies demonstrated that 90Y-DOTATOC and 177Lu-DOTATATE are able to deliver high doses to somatostatin receptor sst2-expressing tumors and low doses to normal organs. RESULTS AND CONCLUSIONS Clinical studies...
متن کاملSurvival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
The NETTER-1 trial demonstrated significantly improved progression-free survival (PFS) for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) emphasizing the high demand for response prediction in appropriate candidates. In this multicenter study, we aimed to elucidate the prognostic value of tumor heterogeneity as assessed by somatostatin receptor (SSTR)-PET/CT. 141 pa...
متن کاملPeptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments
Peptide receptor radionuclide therapy (PRRT) has been shown to be an effective treatment for neuroendocrine tumors (NETs) if curative surgery is not an option. A majority of NETs abundantly express somatostatin receptors. Consequently, following administration of somatostatin (SST) analogs labeled with γ-emitting radionuclides, these tumors can be imaged for diagnosis, staging or follow-up purp...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Cancer
سال: 2001
ISSN: 0020-7136,1097-0215
DOI: 10.1002/1097-0215(20010601)92:5<628::aid-ijc1244>3.3.co;2-c